A phase 1, dose-finding open label clinical infection, safety and viral detectionoptimization in healthy volunteers immunologically experienced against SARS-CoV-2.
The aim of this phase 1 dose escalation study is to develop a safe human infection model
with SARS-CoV-2 in healthy volunteers who have previously been vaccinated against SARS
CoV-2 and either have been infected with SARS-CoV-2 and have evidence of this, or have
developed antibodies against SARS-CoV-2. Increasing titres of SARS-CoV-2 Omicron BA.5
subvariant (starting from 1x10^5 TCID50, up to 1x10^8 TCID50) will be administered
intranasally to different groups of 5-7 volunteers. This is in order to achieve a 50%-75%
attack rate as determined by two or more quantifiable qRT-PCR detections at two
consecutive timepoints from 2 days post-challenge.
A Data Safety Monitoring Board (DSMB) will review safety and quantitative virology data
at each dose level and will recommend continuation, dose escalation or de-escalation,
based on emergent data. Dose escalation will take place in increments of up to 10 times
the previous dose. Once the optimal dose of SARS-CoV-2 Omicron BA.5 subvariant has been
identified in group 1, further inoculations in group 2 may proceed following DSMB review
of infection rate, viral load and clinical data. Group 1 will enrol up to 28 participants
whilst up to 24 participants will be enrolled into Group 2 across several sites.
Rescue therapy with Paxlovid or alternative agents subject to local site availability
(e.g. Remdesivir) will be administered to infected participants after any warning signs
or symptoms of COVID-19 beyond mild disease.
Volunteers with PCR positivity from 2 days post-challenge will remain in negative
pressure isolation rooms within the clinical trials unit for a minimum of 14 days
post-inoculation, and until no viable virus is found in two consecutive samples and a
negative or decreasing viral load is demonstrated by qRT-PCR. Volunteers without PCR
positivity from 2 days post-challenge will remain in negative pressure isolation rooms
within the clinical trials unit for a minimum of 11 days post-inoculation.
Biological: Omicron BA.5 SARS-CoV-2 challenge virus
The SARS-CoV-2 challenge virus strain was originally obtained from a nose/throat swab
taken from a patient who developed respiratory symptoms consistent with Covid-19. All
manufacturing steps are carried out in accordance with GMP by BioMARC, operating out of
Colorado State University.
Inclusion Criteria:
1. Aged 18-40 years at the time of enrolment.
2. Evidence of having had at least one Covid-19 vaccine, with the last vaccination at
least 3 months before enrolment.
3. Positive serology for SARS-CoV-2 at screening OR evidence of prior infection with
SARS-CoV-2 (Evidence will be assessed by a clinician and may include evidence of a
positive PCR result, a photograph of a positive lateral flow on the volunteer's
phone or anti-nucleocapsid positivity at any time).
4. Body Mass Index (BMI) ≥18.5 kg/m2 and ≤28 kg/m2 at admission to the quarantine unit.
The upper limit of BMI may be increased to ≤30kg/m2 at the PI's discretion, in the
case of a physically fit muscular individual.
5. In good health with no history of clinically significant medical conditions (as
described in Exclusion criteria) that would interfere with subject safety, as
defined by medical history, physical examination, routine laboratory tests, ECG,
spirometry and Chest X-Ray as determined by the Investigator at a screening
evaluation.
6. Willing and able to provide written informed consent for participation in the study.
7. Willing to allow the investigators to discuss the volunteer's medical history with
their General Practitioner or any relevant health authority.
8. Allow the investigator to register volunteer details with a confidential database
(The Over-volunteering Protection Service) to prevent concurrent entry into clinical
studies/trials.
9. Agreement to refrain from blood donation during the course of the study.
10. For people of child bearing potential (POCBP): a willingness to practice continuous
effective contraception (see below) from 4 weeks before admission to the quarantine
unit until discharge from the quarantine unit, and negative pregnancy tests on
screening (urine) and pre-enrolment admission days (urine and serum).
11. Agree to abstain from sexual activity or use effective contraception from the start
of treatment with Paxlovid until 7 days after completing treatment with Paxlovid
should they receive it. For people of child bearing potential (POCBP) taking the
combined oral contraceptive pill, a willingness to use barrier contraception during
treatment with Paxlovid and until completion of one menstrual cycle after completing
Paxlovid treatment.
12. Able and willing (in the investigator's opinion) to comply with all study
requirements.
13. No clinically relevant findings in medical history or on physical examination.
Exclusion Criteria:
1. History or evidence of any clinically significant or currently active
cardiovascular, (including thromboembolic events), respiratory, dermatological,
gastrointestinal, endocrine, haematological, hepatic, immunological,
rheumatological, metabolic, urological, renal, neurological or psychiatric illness.
Specifically:
a) Subjects with any history of physician diagnosed and/or objective test confirmed
asthma, chronic obstructive pulmonary disease, pulmonary hypertension, reactive
airway disease, or chronic lung condition of any aetiology or who have experienced:
i) Significant/severe wheeze in the past. ii) Severe respiratory illness as judged
by the investigator (e.g. hospitalisation for pneumonia as an adult).
iii) Known bronchial hyperreactivity to viruses. b) History of thromboembolic,
cardiovascular or cerebrovascular disease. c) History or evidence of diabetes
mellitus. d) Any concurrent serious illness including history of malignancy that
could interfere with the aims of the study or a subject completing the study. Basal
cell carcinoma within 5 years of cure or with evidence of recurrence is also an
exclusion.
e) Migraine with aura. Cluster headache/migraine requiring prophylactic treatment.
f) History or evidence of autoimmune disease or known immunocompromised state of any
cause.
g) Psychiatric illness including subjects with a history of depression and/or
anxiety with associated severe psychiatric comorbidities, for example psychosis.
Consider exclusion in the following cases i) Subjects with history of
anxiety-related symptoms of any severity within the last 2 years if the Generalized
Anxiety Disorder-7 score is ≥5.
ii) Subjects with a history of depression of any severity within the last 2 years if
the Patient Health Questionnaire-9 score is ≥4.
h) Bleeding disorder (e.g. factor deficiency, coagulopathy or platelet disorder), or
prior history of significant bleeding or bruising following injections or
venepuncture.
i) Other major disease that, in the opinion of the Investigator, could interfere
with a subject completing the study and necessary investigations.
2. Significant smoking history, defined as:
1. Current active smokers, equivalent to >5 cigarettes per week, including use of
tobacco in any form (e.g., smoking or chewing) or other nicotine-containing
products in any form (e.g., gum, patch or electronic cigarettes).
2. Ex-smokers: Participants who have smoked ≥5 pack years at any time [5 pack
years is equivalent to one pack of 20 cigarettes a day for 5 years] or the
equivalent amount of nicotine if using tobacco in alternative forms.
- Ex-smokers that have smoked <5 pack years at any time must have not smoked
in the last 3 months.
3. History or presence of alcohol addiction, or excessive use of alcohol (average
weekly intake in excess of 28 units alcohol; one unit being a half glass of beer, a
small glass of wine or a measure of spirits).
4. Clinically significant history of drug misuse, with evidence of a negative urine
drug and nicotine screen required at quarantine admission.
5. History of anaphylaxis or any allergy likely to be worsened by any component of the
study agent or proposed treatment regime.
6. Clinically active rhinitis (including hay fever) or history of moderate to severe
rhinitis, or history of seasonal allergic rhinitis likely to be active at time of
inclusion into the study and/or requiring regular nasal corticosteroids on at least
weekly basis, within 30 days of enrolment.
7. Any significant abnormality altering the anatomy of the nose or nasopharynx,
clinically significant history of epistaxis (nose bleeds) or any nasal or sinus
surgery within six months of inoculation.
8. Positive HBV, HCV or HIV screening serology.
9. Concurrent use of oral, inhaled or systemic steroid medication or use within 6
months of enrolment (steroids used as a cream or ointment are permissible), or the
use of other immunosuppressive agents concurrently or within 6 months of enrolment.
10. Administration of immunoglobulins and/or any blood products within the three months
preceding the planned study challenge date.
11. Current use of any medication or other drug taken through the nasal or inhaled route
including cocaine or other recreational drugs.
12. Current pregnancy or pregnancy within 6 months of enrolment, lactation or intention
to become pregnant during study period.
13. Those in close domestic contact (i.e. sharing a household with, caring for, or daily
face to face contact) with children under 2 years, the elderly (>65 years),
immunosuppressed persons, or those with chronic respiratory disease.
14. Participation in another research study or trial involving receipt of an
investigational product in the 30 days preceding enrolment, or planned use during
the study period.
15. Confirmed Covid-19 in the 3 months prior to enrolment.
16. Evidence of ongoing post Covid-19 symptoms or complications e.g. pulmonary fibrosis
on chest X-ray.
17. Previous hospitalisation with Covid-19 disease or related complications or unusually
severe or protracted symptoms of Covid-19, as judged by the investigator.
18. Family history of 1st degree relative aged 50 years or less with sudden cardiac or
unexplained death.
19. Family history of severe Covid-19 disease or response to any other viral disease
e.g. Guillain-Barré.
20. Clinically significant abnormality on screening chest radiograph.
21. History of a clinically significant abnormality of spirometry.
22. Any clinically significant abnormality of screening blood or urine tests.
23. Receipt of any vaccine within the preceding 30 days from enrolment or has plans to
receive a vaccine before the day 28 follow-up visit.
24. Any other significant disease, disorder, or finding, which, in the opinion of the
investigator, may either put the volunteer at risk, affect the volunteer's ability
to participate in the study or impair interpretation of the study data.
25. Venous access considered inadequate for the phlebotomy and cannulation demands of
the study.
26. Use of medication that interacts with Paxlovid (unless an alternative rescue therapy
is available, the study doctor will be able to advise on this).
Centre for Clinical Vaccinology and Tropical Medicine
Oxford, Oxfordshire, United Kingdom
Helen McShane, MD PhD, Principal Investigator
University of Oxford